FI961220A0 - Asyloitu insuliini - Google Patents

Asyloitu insuliini

Info

Publication number
FI961220A0
FI961220A0 FI961220A FI961220A FI961220A0 FI 961220 A0 FI961220 A0 FI 961220A0 FI 961220 A FI961220 A FI 961220A FI 961220 A FI961220 A FI 961220A FI 961220 A0 FI961220 A0 FI 961220A0
Authority
FI
Finland
Prior art keywords
amino acid
acid residue
lys
present
cys
Prior art date
Application number
FI961220A
Other languages
English (en)
Swedish (sv)
Other versions
FI961220A (fi
FI117055B (fi
Inventor
Svend Havelund
John Broberg Halstrom
Ib Jonassen
Asser Sloth Andersen
Jan Markussen
Original Assignee
Novo Nordisk As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26065125&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FI961220(A0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from DK104493A external-priority patent/DK104493D0/da
Application filed by Novo Nordisk As filed Critical Novo Nordisk As
Publication of FI961220A0 publication Critical patent/FI961220A0/fi
Publication of FI961220A publication Critical patent/FI961220A/fi
Application granted granted Critical
Publication of FI117055B publication Critical patent/FI117055B/fi

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/01—DNA viruses
    • C07K14/02—Hepadnaviridae, e.g. hepatitis B virus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/62—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Toxicology (AREA)
  • Emergency Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
FI961220A 1993-09-17 1996-03-15 Menetelmä asyloidun insuliinin valmistamiseksi FI117055B (fi)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
DK104493 1993-09-17
DK104493A DK104493D0 (da) 1993-09-17 1993-09-17 Hidtil ukendte peptider
US19082994A 1994-02-02 1994-02-02
US19082994 1994-02-02
DK9400347 1994-09-16
PCT/DK1994/000347 WO1995007931A1 (en) 1993-09-17 1994-09-16 Acylated insulin

Publications (3)

Publication Number Publication Date
FI961220A0 true FI961220A0 (fi) 1996-03-15
FI961220A FI961220A (fi) 1996-05-14
FI117055B FI117055B (fi) 2006-05-31

Family

ID=26065125

Family Applications (1)

Application Number Title Priority Date Filing Date
FI961220A FI117055B (fi) 1993-09-17 1996-03-15 Menetelmä asyloidun insuliinin valmistamiseksi

Country Status (30)

Country Link
US (1) US5750497A (fi)
EP (2) EP1132404A3 (fi)
JP (3) JP3014764B2 (fi)
KR (1) KR100310122B1 (fi)
CN (1) CN1056618C (fi)
AT (1) ATE204882T1 (fi)
AU (2) AU682061B2 (fi)
BG (1) BG61611B1 (fi)
BR (1) BR9407508A (fi)
CA (1) CA2171424C (fi)
CZ (1) CZ287945B6 (fi)
DE (2) DE122004000035I2 (fi)
DK (1) DK0792290T3 (fi)
ES (1) ES2163451T3 (fi)
FI (1) FI117055B (fi)
FR (1) FR04C0020I2 (fi)
HU (1) HU217684B (fi)
IL (1) IL110977A (fi)
LU (1) LU91101I2 (fi)
NL (1) NL300160I2 (fi)
NO (3) NO316944B1 (fi)
NZ (1) NZ273285A (fi)
PL (1) PL178466B1 (fi)
PT (1) PT792290E (fi)
RO (1) RO112873B1 (fi)
RU (1) RU2164520C2 (fi)
SI (1) SI0792290T1 (fi)
SK (1) SK282495B6 (fi)
UA (1) UA45321C2 (fi)
WO (1) WO1995007931A1 (fi)

Families Citing this family (184)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9316895D0 (en) * 1993-08-13 1993-09-29 Guy S And St Thomas Hospitals Hepatoselective insulin analogues
US6342225B1 (en) 1993-08-13 2002-01-29 Deutshces Wollforschungsinstitut Pharmaceutical active conjugates
US6869930B1 (en) * 1993-09-17 2005-03-22 Novo Nordisk A/S Acylated insulin
DE4437604A1 (de) * 1994-10-21 1996-04-25 Basf Ag Konjugate aus einem Poly- oder Oligopeptid und einer niedermolekularen lipophilen Verbindung
US5693609A (en) * 1994-11-17 1997-12-02 Eli Lilly And Company Acylated insulin analogs
US5646242A (en) * 1994-11-17 1997-07-08 Eli Lilly And Company Selective acylation of epsilon-amino groups
US6251856B1 (en) 1995-03-17 2001-06-26 Novo Nordisk A/S Insulin derivatives
CZ289343B6 (cs) * 1995-03-17 2002-01-16 Novo Nordisk A/S Inzulinový derivát a farmaceutický prostředek pro léčení diabetes
US20010041786A1 (en) * 1995-06-07 2001-11-15 Mark L. Brader Stabilized acylated insulin formulations
GB9513967D0 (en) * 1995-07-08 1995-09-06 Univ Leicester Insulin
US6451970B1 (en) 1996-02-21 2002-09-17 Novo Nordisk A/S Peptide derivatives
ATE208208T1 (de) * 1996-06-20 2001-11-15 Novo Nordisk As Halogenid-enthaltende insulinzubereitungen
US5905140A (en) * 1996-07-11 1999-05-18 Novo Nordisk A/S, Novo Alle Selective acylation method
WO1998002460A1 (en) * 1996-07-11 1998-01-22 Novo Nordisk A/S Selective acylation method
US6458924B2 (en) 1996-08-30 2002-10-01 Novo Nordisk A/S Derivatives of GLP-1 analogs
US7235627B2 (en) 1996-08-30 2007-06-26 Novo Nordisk A/S Derivatives of GLP-1 analogs
US20020025933A1 (en) * 1996-08-30 2002-02-28 Knudsen Liselotte Bjerre GLP-2 derivatives
US6268343B1 (en) 1996-08-30 2001-07-31 Novo Nordisk A/S Derivatives of GLP-1 analogs
US5898067A (en) * 1997-02-07 1999-04-27 Novo Nordisk A/S Crystallization of proteins
WO1998042749A1 (en) * 1997-03-20 1998-10-01 Novo Nordisk A/S Zinc free insulin crystals for use in pulmonary compositions
US6043214A (en) * 1997-03-20 2000-03-28 Novo Nordisk A/S Method for producing powder formulation comprising an insulin
US6310038B1 (en) 1997-03-20 2001-10-30 Novo Nordisk A/S Pulmonary insulin crystals
EP0911035A3 (en) * 1997-10-24 2002-08-21 Eli Lilly And Company Insoluble insulin compositions
IL134901A0 (en) * 1997-10-24 2001-05-20 Lilly Co Eli Insoluble insulin compositions
US6451762B1 (en) 1997-10-24 2002-09-17 Novo Nordisk A/S Aggregates of human insulin derivatives
US6444641B1 (en) 1997-10-24 2002-09-03 Eli Lilly Company Fatty acid-acylated insulin analogs
ZA989744B (en) * 1997-10-31 2000-04-26 Lilly Co Eli Method for administering acylated insulin.
EP1396272A1 (en) * 1997-12-23 2004-03-10 Eli Lilly & Company Insoluble Insulin Compositions for Controlling Blood Glucose
CO4970787A1 (es) * 1997-12-23 2000-11-07 Lilly Co Eli Composiciones insolubles de insulina y derivados de insulina que controlan la glucosa sanguinea
DE69924232D1 (de) * 1998-01-09 2005-04-21 Novo Nordisk As Stabilisierte insulin-zubereitungen
EP1060192A2 (en) * 1998-02-27 2000-12-20 Novo Nordisk A/S Glp-2 derivatives with helix-content exceeding 25 %, forming partially structured micellar-like aggregates
DE19825447A1 (de) * 1998-06-06 1999-12-09 Hoechst Marion Roussel De Gmbh Neue Insulinanaloga mit erhöhter Zinkbildung
AU8029798A (en) * 1998-06-12 2000-01-05 Deutsches Wollforschungsinstitut Insulin analogue
US7169889B1 (en) * 1999-06-19 2007-01-30 Biocon Limited Insulin prodrugs hydrolyzable in vivo to yield peglylated insulin
JP2003528149A (ja) 2000-03-24 2003-09-24 ジェネンテック・インコーポレーテッド 軟骨性疾患の治療のためのインスリンの使用
WO2001085256A2 (en) * 2000-05-05 2001-11-15 Novo Nordisk A/S Critical illness neuropathy
US7316999B2 (en) 2000-06-02 2008-01-08 Novo Nordisk A/S Glucose dependent release of insulin from glucose sensing insulin derivatives
EP1299418A1 (en) * 2000-07-10 2003-04-09 BTG INTERNATIONAL LIMITED (Company No. 2664412) Insulin derivatives and synthesis thereof
KR20030005204A (ko) * 2000-12-25 2003-01-17 가부시키가이샤 시세이도 교감신경 활성화 향료 조성물
US6867183B2 (en) * 2001-02-15 2005-03-15 Nobex Corporation Pharmaceutical compositions of insulin drug-oligomer conjugates and methods of treating diseases therewith
US7060675B2 (en) * 2001-02-15 2006-06-13 Nobex Corporation Methods of treating diabetes mellitus
ATE338055T1 (de) * 2001-05-02 2006-09-15 Novo Nordisk As Verfahren zur herstellung von gallensäure
US6653492B2 (en) 2001-05-02 2003-11-25 Novo Nordick A/S Preparation of bile acids
US6828297B2 (en) * 2001-06-04 2004-12-07 Nobex Corporation Mixtures of insulin drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
US6828305B2 (en) * 2001-06-04 2004-12-07 Nobex Corporation Mixtures of growth hormone drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
US7713932B2 (en) * 2001-06-04 2010-05-11 Biocon Limited Calcitonin drug-oligomer conjugates, and uses thereof
US6858580B2 (en) * 2001-06-04 2005-02-22 Nobex Corporation Mixtures of drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
US6835802B2 (en) * 2001-06-04 2004-12-28 Nobex Corporation Methods of synthesizing substantially monodispersed mixtures of polymers having polyethylene glycol moieties
US6713452B2 (en) * 2001-06-04 2004-03-30 Nobex Corporation Mixtures of calcitonin drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
US7595172B2 (en) 2001-07-24 2009-09-29 Novo Nordisk A/S Method for making acylated polypeptides
JP2005508895A (ja) 2001-08-28 2005-04-07 イーライ・リリー・アンド・カンパニー Ｇｌｐ−１および基礎インスリンの予備混合物
US7176278B2 (en) 2001-08-30 2007-02-13 Biorexis Technology, Inc. Modified transferrin fusion proteins
US7196059B2 (en) * 2001-09-07 2007-03-27 Biocon Limited Pharmaceutical compositions of insulin drug-oligomer conjugates and methods of treating diseases therewith
US7166571B2 (en) * 2001-09-07 2007-01-23 Biocon Limited Insulin polypeptide-oligomer conjugates, proinsulin polypeptide-oligomer conjugates and methods of synthesizing same
US6913903B2 (en) * 2001-09-07 2005-07-05 Nobex Corporation Methods of synthesizing insulin polypeptide-oligomer conjugates, and proinsulin polypeptide-oligomer conjugates and methods of synthesizing same
US7312192B2 (en) * 2001-09-07 2007-12-25 Biocon Limited Insulin polypeptide-oligomer conjugates, proinsulin polypeptide-oligomer conjugates and methods of synthesizing same
PT1430082E (pt) 2001-09-07 2010-01-15 Biocon Ltd Métodos de síntese de conjugados de polipéptido de insulina-oligómero, e conjugados de polipéptido de pró-insulina-oligómero e método de síntese dos mesmos
WO2003031432A1 (en) 2001-10-12 2003-04-17 Novo Nordisk A/S Substituted piperidines and their use for the treatment of diseases related to the histamine h3 receptor
WO2003035099A1 (en) 2001-10-19 2003-05-01 Eli Lilly And Company Biphasic mixtures of glp-1 and insulin
KR100925381B1 (ko) 2001-11-19 2009-11-09 노보 노르디스크 에이/에스 인슐린 화합물의 제조 방법
GB0206792D0 (en) 2002-03-22 2002-05-01 Leuven K U Res & Dev Normoglycemia
WO2003094956A1 (en) * 2002-05-07 2003-11-20 Novo Nordisk A/S Soluble formulations comprising monomeric insulin and acylated insulin
US20040038864A1 (en) * 2002-06-27 2004-02-26 Per Balschmidt Use of dimethyl sulfone as isotonicity agent
US7273921B2 (en) 2002-09-25 2007-09-25 Novo Nordisk A/S Method for producing acylated peptides
CN100586926C (zh) * 2002-09-25 2010-02-03 诺沃娜第克公司 制备酰化肽的方法
US7411039B2 (en) 2002-10-14 2008-08-12 Novo Nordisk A/S GLP-2 compounds, formulations, and uses thereof
US20040138099A1 (en) * 2002-11-29 2004-07-15 Draeger Eberhard Kurt Insulin administration regimens for the treatment of subjects with diabetes
WO2004085472A1 (en) * 2003-03-27 2004-10-07 Novo Nordisk A/S Method for making human insulin precursors and human insulin
EP1615698B1 (en) 2003-04-11 2010-09-29 High Point Pharmaceuticals, LLC New amide derivatives and pharmaceutical use thereof
WO2004096266A1 (en) * 2003-05-02 2004-11-11 Novo Nordisk A/S Improved physical stability of insulin formulations
WO2005000580A1 (en) 2003-06-27 2005-01-06 Novo Nordisk A/S High moisture barrier container for medical liquid compositions
RU2352581C2 (ru) 2003-08-05 2009-04-20 Ново Нордиск А/С Производные инсулина
WO2005012347A2 (en) 2003-08-05 2005-02-10 Novo Nordisk A/S Novel insulin derivatives
WO2005047508A1 (en) 2003-11-14 2005-05-26 Novo Nordisk A/S Processes for making acylated insulin
CN104826116A (zh) 2003-11-20 2015-08-12 诺沃挪第克公司 对于生产和用于注射装置中是最佳的含有丙二醇的肽制剂
EP1692168B1 (en) 2003-12-03 2011-07-20 Novo Nordisk A/S Single-chain insulin
DE602004029496D1 (de) 2003-12-22 2010-11-18 Novo Nordisk As Offbehälter zur lagerung von pharmazeutischen flüssigkeiten
EP2842576B1 (en) 2004-01-21 2017-06-28 Novo Nordisk Health Care AG Transglutaminase mediated conjugation of peptides
PT1740154E (pt) * 2004-03-12 2009-09-11 Biodel Inc Composições de insulina com absorção melhorada
WO2006008238A1 (en) * 2004-07-16 2006-01-26 Novo Nordisk A/S Method for selective acylation
UA91512C2 (ru) 2004-07-19 2010-08-10 Биокон Лимитед Коньюгати олигомеров инсулина, их композиция (варианты) и применение
US7833513B2 (en) 2004-12-03 2010-11-16 Rhode Island Hospital Treatment of Alzheimer's Disease
ES2438145T3 (es) 2005-02-02 2014-01-16 Novo Nordisk A/S Nuevos derivados de insulina
US20080171695A1 (en) 2005-02-02 2008-07-17 Novo Nordisk A/S Insulin Derivatives
JP2008542235A (ja) * 2005-05-25 2008-11-27 ノボ・ノルデイスク・エー／エス 安定化ポリペプチド製剤
US8097584B2 (en) 2005-05-25 2012-01-17 Novo Nordisk A/S Stabilized formulations of insulin that comprise ethylenediamine
EP1888104A2 (en) * 2005-05-26 2008-02-20 Novo Nordisk A/S Acylated insulin with high purity
CN103110635A (zh) 2005-07-04 2013-05-22 海波因特制药有限责任公司 组胺h3受体拮抗剂
ES2426345T3 (es) 2005-07-20 2013-10-22 Eli Lilly And Company Compuesto unidos en posición 1-amino
US9056921B2 (en) 2005-08-16 2015-06-16 Novo Nordisk A/S Method for making mature insulin polypeptides
US7741281B2 (en) * 2005-11-03 2010-06-22 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
ES2393757T3 (es) 2005-11-17 2012-12-27 Eli Lilly & Company Antagonistas de receptor de glucagón, preparación y usos terapéuticos
EP2505593A1 (en) 2005-12-28 2012-10-03 Novo Nordisk A/S Compositions comprising an acylated insulin and zinc and method of making the said compositions
US20070196416A1 (en) 2006-01-18 2007-08-23 Quest Pharmaceutical Services Pharmaceutical compositions with enhanced stability
ES2387955T3 (es) * 2006-02-27 2012-10-04 Novo Nordisk A/S Derivados de insulina
WO2007104737A1 (en) * 2006-03-13 2007-09-20 Novo Nordisk A/S Acylated single chain insulin
WO2007104786A1 (en) 2006-03-15 2007-09-20 Novo Nordisk A/S Mixtures of amylin and insulin
AU2007229492B2 (en) 2006-03-28 2011-11-03 High Point Pharmaceuticals, Llc Benzothiazoles having histamine H3 receptor activity
EP2049475B1 (en) 2006-04-24 2012-02-01 Eli Lilly & Company Cyclohexyl substituted pyrrolidinones as inhibitors of 11-beta-hydroxysteroid dehydrogenase 1
CN101437849B (zh) * 2006-05-09 2015-09-30 诺沃-诺迪斯克有限公司 胰岛素衍生物
ES2395738T3 (es) 2006-05-09 2013-02-14 Novo Nordisk A/S Derivado de insulina
EP2024390B1 (en) * 2006-05-09 2015-08-19 Novo Nordisk A/S Insulin derivative
US7714025B2 (en) * 2006-05-10 2010-05-11 Arizona Biomedical Research Commission Modified chalcone compounds as antimitotic agents
CA2659570C (en) 2006-05-29 2015-10-06 High Point Pharmaceuticals, Llc 3-(1,3-benzodioxol-5-yl)-6-(4-cyclopropylpiperazin-1-yl)-pyridazine, its salts and solvates and its use as histamine h3 receptor antagonist
DK2054073T3 (da) 2006-07-11 2015-03-02 Foresee Pharmaceuticals Inc Farmaceutiske præparater til fremføring med langvarig frigivelse af peptider
CN101573133B (zh) 2006-07-31 2014-08-27 诺沃-诺迪斯克有限公司 Peg化延长的胰岛素
BRPI0717098B8 (pt) 2006-09-22 2021-05-25 Novo Nordisk As análogos de insulina humana resistentes à protease, composição farmacêutica e processo para sua preparação
JP5503968B2 (ja) 2006-09-27 2014-05-28 ノボ・ノルデイスク・エー／エス 成熟インスリンポリペプチドの作製方法
WO2008049711A1 (en) * 2006-10-27 2008-05-02 Novo Nordisk A/S Peptide extended insulins
EP2502618A3 (en) 2007-04-30 2012-10-03 Novo Nordisk A/S Method for drying a protein composition, a dried protein composition and a pharmaceutical composition comprising the dried protein
CA2716159A1 (en) 2007-06-01 2008-12-04 Novo Nordisk A/S Stable non-aqueous pharmaceutical compositions
JP2011504871A (ja) 2007-06-01 2011-02-17 ノボ・ノルデイスク・エー／エス 固体又は半固体担体中にペプチド薬剤を含む自然に分散可能なプレコンセントレイト
CN101677947B (zh) 2007-06-13 2013-07-17 诺沃-诺迪斯克有限公司 包含胰岛素衍生物的药物制剂
US8575096B2 (en) 2007-08-13 2013-11-05 Novo Nordisk A/S Rapid acting insulin analogues
US9241908B2 (en) * 2007-10-16 2016-01-26 Biocon Limited Orally administrable solid pharmaceutical composition and a process thereof
EP2058330A1 (en) * 2007-11-08 2009-05-13 Novo Nordisk A/S Insulin derivative
WO2009060071A1 (en) * 2007-11-08 2009-05-14 Novo Nordisk A/S Insulin derivative
ES2612736T3 (es) 2007-11-16 2017-05-18 Novo Nordisk A/S Composiciones farmacéuticas estables que comprenden liraglutida y degludec
CA2711561A1 (en) * 2008-01-04 2009-07-16 Biodel, Inc. Insulin formulations for insulin release as a function of tissue glucose levels
CN101970477B (zh) 2008-03-14 2014-12-31 诺沃-诺迪斯克有限公司 蛋白酶稳定的胰岛素类似物
KR20110004366A (ko) 2008-03-18 2011-01-13 노보 노르디스크 에이/에스 프로테아제 안정화되고, 아실화된 인슐린 유사체
TWI451876B (zh) 2008-06-13 2014-09-11 Lilly Co Eli 聚乙二醇化之離脯胰島素化合物
PL2307441T3 (pl) 2008-08-07 2016-09-30 Sposób otrzymywania związków insuliny
US9603904B2 (en) 2008-10-30 2017-03-28 Novo Nordisk A/S Treating diabetes melitus using insulin injections with less than daily injection frequency
KR20110088575A (ko) 2008-11-21 2011-08-03 하이 포인트 파마슈티칼스, 엘엘씨 아다만틸 벤즈아미드 화합물
MA33064B1 (fr) * 2009-01-28 2012-02-01 Smartcells Inc Systemes à base de conjugués pour administration contrôlée de médicaments
WO2010088286A1 (en) 2009-01-28 2010-08-05 Smartcells, Inc. Synthetic conjugates and uses thereof
US9060927B2 (en) * 2009-03-03 2015-06-23 Biodel Inc. Insulin formulations for rapid uptake
AU2010226243A1 (en) 2009-03-20 2011-09-22 Smartcells, Inc. Terminally-functionalized conjugates and uses thereof
US20120134977A1 (en) 2009-06-01 2012-05-31 Yeda Research And Development Co. Ltd. Prodrugs containing albumin binding probe
AU2010323117B2 (en) 2009-11-25 2015-09-03 Capsugel Belgium Nv Mucosal delivery compositions comprising a peptide complexed with a crown comppound and/or a counter ion
EP2460527A1 (en) 2010-01-21 2012-06-06 Sanofi Pharmaceutical composition for treating a metabolic syndrome
US9981017B2 (en) 2010-04-02 2018-05-29 Hanmi Science Co., Ltd. Insulin conjugate using an immunoglobulin fragment
AR081066A1 (es) * 2010-04-02 2012-06-06 Hanmi Holdings Co Ltd Conjugado de insulina donde se usa un fragmento de inmunoglobulina
TW201141513A (en) 2010-04-14 2011-12-01 Sanofi Aventis Insulin-siRNA conjugates
BR112012028766A2 (pt) * 2010-05-10 2017-06-13 Novo Nordisk As processo para a preparação de complexos de insulina e zinco
US20140315797A1 (en) * 2010-10-15 2014-10-23 Peter Madsen Novel N-Terminally Modified Insulin Derivatives
JP6049625B2 (ja) 2010-10-27 2016-12-21 ノヴォ ノルディスク アー／エス 様々な注射間隔を用いて施されるインスリン注射を使用する、真性糖尿病の治療
CA2822591C (en) 2010-12-22 2020-12-29 Baxter International Inc. Materials and methods for conjugating a water soluble fatty acid derivative to a protein
WO2012098462A1 (en) 2011-01-20 2012-07-26 Zealand Pharma A/S Combination of acylated glucagon analogues with insulin analogues
WO2012104834A1 (en) 2011-02-03 2012-08-09 Pharmedica Ltd. New oral dissolving films for insulin administration, for treating diabetes
EP2696897A2 (en) 2011-04-11 2014-02-19 Yeda Research and Development Co. Ltd. Albumin binding probes and drug conjugates thereof
EP2548570A1 (en) 2011-07-19 2013-01-23 Sanofi Pharmaceutical composition for treating a metabolic syndrome
CN102504022A (zh) * 2011-11-30 2012-06-20 苏州元基生物技术有限公司 含有保护赖氨酸的胰岛素原及使用其制备胰岛素的方法
AU2012350586B2 (en) 2011-12-15 2017-02-02 Jiangsu Hengrui Medicine Co., Ltd. Human insulin analogue and acylated derivative thereof
ES2594303T3 (es) 2012-04-11 2016-12-19 Novo Nordisk A/S Formulaciones de insulina
RU2670106C2 (ru) 2012-05-01 2018-10-18 Ново Нордиск А/С Фармацевтическая композиция
US9707276B2 (en) 2012-12-03 2017-07-18 Merck Sharp & Dohme Corp. O-glycosylated carboxy terminal portion (CTP) peptide-based insulin and insulin analogues
US10137172B2 (en) 2013-04-30 2018-11-27 Novo Nordisk A/S Administration regime
CA2924109A1 (en) 2013-09-13 2015-03-19 The California Institute For Biomedical Research Modified therapeutic agents and compositions thereof
US9896496B2 (en) * 2013-10-07 2018-02-20 Novo Nordisk A/S Derivative of an insulin analogue
CA2933701C (en) 2013-12-18 2022-05-31 The California Institute For Biomedical Research Modified therapeutic agents, stapled peptide lipid conjugates, and compositions thereof
AR099569A1 (es) 2014-02-28 2016-08-03 Novo Nordisk As Derivados de insulina y los usos médicos de estos
WO2015196174A1 (en) 2014-06-20 2015-12-23 Greene Howard E Infusion delivery devices and methods
CN107921098A (zh) 2015-06-17 2018-04-17 加州生物医学研究所 修饰的治疗剂及其组合物
WO2017032798A1 (en) 2015-08-25 2017-03-02 Novo Nordisk A/S Novel insulin derivatives and the medical uses hereof
US10815287B2 (en) 2016-08-02 2020-10-27 Jiangsu Hengrui Medicine Co., Ltd. Acylated derivative of human insulin or analogue thereof
US10729636B2 (en) 2016-12-05 2020-08-04 Nuritas Limited Compositions comprising peptide WKDEAGKPLVK
EP3329930A1 (en) 2016-12-05 2018-06-06 Nuritas Limited Pharmaceuctical compositions
CN115154591B (zh) 2016-12-16 2023-04-14 诺和诺德股份有限公司 含胰岛素的药物组合物
SG11202000940XA (en) 2017-08-24 2020-02-27 Novo Nordisk As Glp-1 compositions and uses thereof
US20200283492A1 (en) * 2017-09-29 2020-09-10 Hanmi Pharm Co., Ltd. Long acting protein complex having an enhanced efficiency
EP3727424A4 (en) 2017-12-18 2021-10-27 Merck Sharp & Dohme Corp. CONJUGATE-BASED SYSTEMS FOR CONTROLLED INSULIN RELEASE
EP3740212A4 (en) 2017-12-18 2021-10-27 Merck Sharp & Dohme Corp. CONJUGATE-BASED SYSTEMS FOR CONTROLLED INSULIN DELIVERY
BR112020015238A2 (pt) 2018-02-09 2020-12-29 Jiangsu Hengrui Medicine Co., Ltd. Gene precursor otimizado por códon e gene de peptídeo sinal de análogo de insulina humana
TWI742377B (zh) 2018-05-24 2021-10-11 大陸商江蘇恒瑞醫藥股份有限公司 一種重組人胰島素或其類似物的前驅物的製備方法
US10335464B1 (en) 2018-06-26 2019-07-02 Novo Nordisk A/S Device for titrating basal insulin
KR102666154B1 (ko) 2018-08-08 2024-05-20 주식회사 대웅제약 지속형 인슐린 아날로그 및 그 복합체
AU2019398402A1 (en) 2018-12-11 2021-07-29 Sanofi Insulin analogs having reduced insulin receptor binding affinity
KR20200080748A (ko) 2018-12-27 2020-07-07 주식회사 폴루스 음이온 교환 크로마토그래피를 이용한 인슐린 전구체의 정제방법
KR20200080747A (ko) 2018-12-27 2020-07-07 주식회사 폴루스 인슐린 전구체의 인슐린 효소 전환용 조성물 및 이를 이용하여 인슐린 전구체를 인슐린으로 전환하는 방법
CN111909255A (zh) * 2019-05-10 2020-11-10 宁波鲲鹏生物科技有限公司 胰岛素衍生物及其制备方法
EP4004028A1 (en) 2019-07-31 2022-06-01 Eli Lilly and Company Relaxin analogs and methods of using the same
FI4073097T3 (fi) 2019-12-11 2024-08-13 Novo Nordisk As Uusia insuliinianalogeja ja niiden käyttötapoja
WO2021136293A1 (zh) 2019-12-30 2021-07-08 甘李药业股份有限公司 胰岛素衍生物
BR112022013042A2 (pt) 2019-12-30 2022-10-18 Gan & Lee Pharmaceuticals Co Ltd Composto da fórmula b, formulação farmacêutica, composição farmacêutica, método para tratar ou prevenir hiperglicemia, diabetes e/ou obesidade
CA3165359A1 (en) 2020-02-18 2021-07-22 Dorthe Kot Engelund Glp-1 compositions and uses thereof
BR112022019687A2 (pt) 2020-03-31 2022-12-20 Protomer Tech Inc Conjugados para responsividade seletiva a dióis vicinais
JP2024500284A (ja) 2020-11-19 2024-01-09 プロトマー・テクノロジーズ・インコーポレイテッド 芳香族ホウ素含有化合物及びインスリン類似体
EP4180060A1 (en) 2021-11-15 2023-05-17 Adocia Solid compositions comprising a peptide or a protein and an acylated amino acid
EP4299057A1 (en) 2022-06-30 2024-01-03 Adocia Solid compositions comprising a peptide or a protein and an acylated amino acid
WO2023084118A1 (en) 2021-11-15 2023-05-19 Adocia Solid compositions comprising a peptide or a protein and an acylated amino acid
EP4299071A1 (en) 2022-07-01 2024-01-03 Adocia Compositions comprising a peptide or a protein and an acylated amino acid
WO2024051787A1 (zh) * 2022-09-09 2024-03-14 北京惠之衡生物科技有限公司 一种长效酰化胰岛素衍生物及其应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3823125A (en) * 1969-10-14 1974-07-09 American Home Prod N-aminoacyl-substituted insulins
US3950517A (en) * 1970-05-08 1976-04-13 National Research Development Corporation Insulin derivatives
GB1381273A (en) * 1971-01-28 1975-01-22 Nat Res Dev Insulin derivatives
GB1381274A (en) * 1971-01-28 1975-01-22 Nat Res Dev Insulin derivatives
US3907763A (en) * 1972-03-01 1975-09-23 Bayer Ag Insulin derivatives crosslinked by a dicarboxylic acid moiety
DK319780A (da) * 1980-07-24 1982-01-25 Forenede Bryggerier As Fremgangsmaade til enzymatisk udskiftning af b-30 aminosyren i insuliner
IL68769A (en) * 1983-05-23 1986-02-28 Hadassah Med Org Pharmaceutical compositions containing insulin for oral administration
US5008241A (en) * 1985-03-12 1991-04-16 Novo Nordisk A/S Novel insulin peptides
JPH01254699A (ja) * 1988-04-05 1989-10-11 Kodama Kk インスリン誘導体及びその用途
WO1992001476A1 (en) * 1990-07-26 1992-02-06 University Of Iowa Research Foundation Novel drug delivery systems for proteins and peptides using albumin as a carrier molecule
US5336782A (en) * 1991-04-24 1994-08-09 Kuraray Co., Ltd. Long chain carboxylic acid imide ester

Also Published As

Publication number Publication date
IL110977A (en) 2000-06-29
NO2004006I2 (fi) 2008-02-04
DE69428134D1 (de) 2001-10-04
BG61611B1 (bg) 1998-01-30
EP1132404A2 (en) 2001-09-12
WO1995007931A1 (en) 1995-03-23
EP1132404A3 (en) 2002-03-27
JP2000060556A (ja) 2000-02-29
DE69428134T2 (de) 2002-05-02
IL110977A0 (en) 1994-11-28
LU91101I2 (en) 2004-11-08
FR04C0020I1 (fi) 2004-10-29
JP2002308899A (ja) 2002-10-23
NL300160I2 (nl) 2005-07-01
CA2171424C (en) 2002-06-04
KR100310122B1 (ko) 2002-04-24
DE122004000035I2 (de) 2009-08-06
EP0792290A1 (en) 1997-09-03
NO2017041I1 (no) 2017-08-01
NO2004006I1 (no) 2004-10-11
JP4060583B2 (ja) 2008-03-12
PL178466B1 (pl) 2000-05-31
ES2163451T3 (es) 2002-02-01
HU217684B (hu) 2000-03-28
SK32496A3 (en) 1996-11-06
AU682061B2 (en) 1997-09-18
FR04C0020I2 (fr) 2005-05-27
CA2171424A1 (en) 1995-03-23
RU2164520C2 (ru) 2001-03-27
NL300160I1 (nl) 2004-12-01
DE122004000035I1 (de) 2005-02-24
ATE204882T1 (de) 2001-09-15
CZ287945B6 (cs) 2001-03-14
FI961220A (fi) 1996-05-14
US5750497A (en) 1998-05-12
AU7652094A (en) 1995-04-03
UA45321C2 (uk) 2002-04-15
EP0792290B1 (en) 2001-08-29
BG100420A (bg) 1996-12-31
JPH09502867A (ja) 1997-03-25
HUT75991A (en) 1997-05-28
DK0792290T3 (da) 2001-10-01
RO112873B1 (ro) 1998-01-30
NZ273285A (en) 1997-10-24
NO2017041I2 (no) 2018-11-19
FI117055B (fi) 2006-05-31
PL313444A1 (en) 1996-07-08
NO961070L (no) 1996-05-15
KR960704925A (ko) 1996-10-09
SI0792290T1 (en) 2001-12-31
CN1133598A (zh) 1996-10-16
AU4846197A (en) 1998-02-19
NO961070D0 (no) 1996-03-15
JP3917333B2 (ja) 2007-05-23
HU9600676D0 (en) 1996-05-28
BR9407508A (pt) 1997-01-07
CN1056618C (zh) 2000-09-20
SK282495B6 (sk) 2002-02-05
CZ78996A3 (en) 1996-10-16
NO316944B1 (no) 2004-07-05
JP3014764B2 (ja) 2000-02-28
PT792290E (pt) 2002-01-30

Similar Documents

Publication Publication Date Title
NO2017041I1 (no) Insulin detemir - forlenget SPC
RU96108249A (ru) Ацилированный инсулин
NZ330700A (en) B27, B28, B29 (B chain) insulin derivatives having a rapid onset of action
CA2081659A1 (en) Recombinant human factor viii derivatives
PH27425A (en) Insulin derivatives the use thereof and a pharmaceutical formulation containing them
KR900002801A (ko) 당뇨병 치료용 약학적제제
EP0105759A3 (en) Human pancreatic grf
PL322299A1 (en) Derivatives of insulin
KR920701250A (ko) 신규 인슐린 화합물
IL94939A0 (en) Substitution analogues of magainin peptides
ZA941198B (en) Highly concentrated TCF pharmaceutical preparations
EP0911035A3 (en) Insoluble insulin compositions
Marti et al. Hb Altdorf α2β2 135 (H13) Ala→ Pro: A new electrophoretically silent unstable haemoglobin variant from Switzerland
HU911358D0 (en) Grf analogues
GR3015492T3 (en) ZNS-active hexapeptides with antiamnestic activity.
DK119391A (da) Humaninsulinanaloger

Legal Events

Date Code Title Description
FG Patent granted

Ref document number: 117055

Country of ref document: FI

SPCF Supplementary protection certificate application filed

Spc suppl protection certif: L20060006

SPCG Supplementary protection certificate granted

Spc suppl protection certif: 273

Extension date: 20181110

MA Patent expired
SPCE Application for extension of a supplementary protection certificate [pediatric extension]

Spc suppl protection certif: L20060006

SPCP Extension of a supplementary protection certificate [pediatric extension]

Spc suppl protection certif: 273

Extension date: 20190510